GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ReNeuron Group PLC (LSE:RENE) » Definitions » EPS (Diluted)

ReNeuron Group (LSE:RENE) EPS (Diluted) : £-0.09 (TTM As of Sep. 2023)


View and export this data going back to 2005. Start your Free Trial

What is ReNeuron Group EPS (Diluted)?

ReNeuron Group's Earnings per Share (Diluted) for the six months ended in Sep. 2023 was £-0.05. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 was £-0.09.

ReNeuron Group's EPS (Basic) for the six months ended in Sep. 2023 was £-0.05. Its EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2023 was £-0.09.

ReNeuron Group's EPS without NRI for the six months ended in Sep. 2023 was £-0.05. Its EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2023 was £-0.09.

During the past 3 years, the average EPS without NRIGrowth Rate was 36.00% per year. During the past 5 years, the average EPS without NRI Growth Rate was 29.30% per year. During the past 10 years, the average EPS without NRI Growth Rate was 30.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, ReNeuron Group's highest 3-Year average EPS without NRI Growth Rate was 82.90% per year. The lowest was -267.60% per year. And the median was 18.65% per year.


ReNeuron Group EPS (Diluted) Historical Data

The historical data trend for ReNeuron Group's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ReNeuron Group EPS (Diluted) Chart

ReNeuron Group Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
EPS (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.44 -0.36 -0.29 -0.17 -0.10

ReNeuron Group Semi-Annual Data
Mar14 Sep14 Mar15 Sep15 Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.09 -0.08 -0.06 -0.04 -0.05

Competitive Comparison of ReNeuron Group's EPS (Diluted)

For the Biotechnology subindustry, ReNeuron Group's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ReNeuron Group's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ReNeuron Group's PE Ratio distribution charts can be found below:

* The bar in red indicates where ReNeuron Group's PE Ratio falls into.



ReNeuron Group EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

ReNeuron Group's Diluted EPS for the fiscal year that ended in Mar. 2023 is calculated as

Diluted EPS (A: Mar. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-5.408-0)/57.126
=-0.09

ReNeuron Group's Diluted EPS for the quarter that ended in Sep. 2023 is calculated as

Diluted EPS (Q: Sep. 2023 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-2.841-0)/57.174
=-0.05

EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was £-0.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ReNeuron Group  (LSE:RENE) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


ReNeuron Group EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of ReNeuron Group's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


ReNeuron Group (LSE:RENE) Business Description

Traded in Other Exchanges
Address
Pencoed Business Park, Pencoed, Bridgend, GBR, CF35 5HY
ReNeuron Group PLC is engaged in the field of biotechnology. Its core activities include the research and clinical development of cell-based therapeutics. The company product pipeline includes the human retinal progenitor cell line (hRPC) and CTX neural cell line. It derives revenue from UK and U.S. The company is mainly focusing on the treatment of stroke disability, inherited retinal diseases, and cancer.